Trutect gains full USDA approval for canine parvovirus

Elanco’s canine parvovirus monoclonal antibody, now branded Trutect, has moved from conditional licensure to full USDA approval, giving veterinarians the first fully approved targeted treatment for canine parvovirus in the U.S. The product was first conditionally licensed in May 2023, and the USDA expanded its label in June 2025 to include passive immunity for exposed puppies, adding a preventive use alongside treatment. Elanco says real-world use showed a 93% survival rate in treated puppies and an average hospital stay shortened by 1.87 days. (elanco.com)

Why it matters: For veterinary professionals, this marks a meaningful shift from parvo care built almost entirely around supportive therapy to one that includes a pathogen-targeted biologic. That matters because canine parvovirus remains a devastating disease that attacks rapidly dividing cells, especially in the intestinal lining and bone marrow, driving severe diarrhea, dehydration, leukopenia, and risk of sepsis if untreated. It also arrives in a prevention landscape complicated by maternal antibodies, which can interfere with early vaccination response and leave some puppies vulnerable during the vaccine series. Outside commentary has framed the therapy as a potential practice changer, with AAHA reporting early enthusiasm from clinicians and citing study data in which no treated puppies died in an initial efficacy study of 28 eight-week-old puppies. (aaha.org; fearfreepets.com)

What to watch: Watch for broader protocol adoption, more independent clinical data, and how clinics use the product’s treatment and post-exposure preventive indications in everyday parvo workflows, especially in high-risk settings such as shelters and in young puppies still moving through their vaccine series. (elanco.com)